Troriluzole
Troriluzole is an experimental medication that has been investigated as a potential treatment for Machado–Joseph disease (MJD), obsessive–compulsive disorder (OCD), , spinocerebellar ataxia (SCA), and glioblastoma.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Troriluzole is an experimental medication that has been investigated as a potential treatment for Machado–Joseph disease (MJD), obsessive–compulsive disorder (OCD), , spinocerebellar ataxia (SCA), and glioblastoma. It is a prodrug modification of the medication riluzole.
Pharmacokinetics
While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.
Research
In 2024, researchers published a study in the Journal of Neurochemistry that reported troriluzole could reverse some early Alzheimer's disease brain changes in mice, reduce harmful glutamate levels, and improve memory and learning abilities.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371289850 under CC BY-SA 4.0; modifications have been made.